Revised simulation model does not predict rebound in gonorrhoea prevalence where core groups are treated in the
Molly A Trecker1, Daniel J Hogan2, Cheryl L Waldner3
1Vaccine and Infectious Disease Organization-International Vaccine Centre, Saskatoon, Saskatchewan, Canada School of Public Health, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Objectives:
To determine the effects of using discrete versus continuous quantities of people in a compartmental model examining the contribution of antimicrobial resistance (AMR) to rebound in the prevalence of gonorrhoea.
Methods:
A previously published transmission model was reconfigured to represent the occurrence of gonorrhoea in discrete persons, rather than allowing fractions of infected individuals during simulations.
Results:
In the revised model, prevalence only rebounded under scenarios reproduced from the original paper when AMR occurrence was increased by 10(5) times. In such situations, treatment of high-risk individuals yielded outcomes very similar to those resulting from treatment of low-risk and intermediate-risk individuals. Otherwise, in contrast with the original model, prevalence was the lowest when the high-risk group was treated, supporting the current policy of targeting treatment to high-risk groups.
Conclusions:
Simulation models can be highly sensitive to structural features. Small differences in structure and parameters can substantially influence predicted outcomes and policy prescriptions, and must be carefully considered.
More Related Videos
06:19Author Spotlight: Characterizing Airway Environments to Advance Model Systems and Antimicrobial Discovery in Cystic Fibrosis and Chronic Respiratory Infections
Published on: October 11, 2024
07:16Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis
Published on: September 20, 2024
Related Concept Videos
Development of Antibiotic Resistance
Clinical Significance of Antibiotic Resistance
Antimicrobial Effectiveness
Antibiotic Selection
Mechanism of Antibiotic Resistance in MRSA
Sexually Transmitted Infections
